Background: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is considered the standard of care for multiple myeloma (MM) patients <65 years. Safety and outcome of ASCT for patients >65 years is currently uncertain, especially since the introduction of novel agents for induction and maintenance therapy. Furthermore, there are no conclusive data available on risk assessment in elderly patients treated with HDT.
introduction High-dose therapy (HDT) with melphalan 200 mg/m 2 (MEL200) followed by autologous stem cell transplantation (ASCT) in combination with novel agents (thalidomide, lenalidomide and bortezomib) is considered the standard of care for patients with newly diagnosed multiple myeloma (MM) younger than 65 years [1, 2] . MM is a disease of the elderly with a median age at diagnosis of 70 years [3] . Therefore, a large proportion of patients are considered ineligible for HDT because of increased treatment related toxicity and mortality of MEL200 and the lack of results from randomized phase III trials with MEL-200 in elderly patients [4] . Previous studies have shown that HDT with intermediate dose (100 mg/m 2 ) melphalan (MEL100) is feasible for elderly myeloma patients up to 75 years of age [5, 6] . The benefit of HDT in these patients compared with the current standard of novel agents with or without chemotherapy is uncertain as in most studies HDT was not supported by the use of novel agents during induction therapy and no maintenance therapy was administered. Furthermore, Palumbo et al. demonstrated that MEL100 is inferior to MEL200 regarding depth of remission and time to progression in younger patients with MM [7] . As a consequence, rates of complete remission (CR) in MEL100 trials were low and *Correspondence to: Dr Jens Hillengass, Department of Medicine V, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Tel: +49-6221-56-39397; Fax: +49-6221-56-4171; E-mail: jens.hillengass@med.uni-heidelberg.de only one prospective trial showed that MEL100 is superior to conventional chemotherapy with melphalan and prednisone (MP) [6] . Furthermore, the Intergroupe Francophone du Myélome (IFM) showed in a phase III trial that the addition of thalidomide to melphalan/prednisone (MPT) was superior to MEL100 in patients between 65 and 75 years [5] .
However, there is still a lack of information about feasibility and outcome of HDT with MEL200 in combination with novel agents in elderly patients. In the current study, we, therefore, retrospectively evaluated the treatment-related toxicity and mortality of elderly MM patients treated with MEL200 followed by ASCT. Additionally, the impact of integrating novel agents into the HDT regimen on remission and outcome was investigated.
patients and methods patients and risk stratification
From January 2007 to September 2012, 202 patients between 60 and 75 years (median age 65 years) with newly diagnosed MM underwent HDT with ASCT in the Department of Hematology and Oncology of the University Hospital of Heidelberg, Germany. The indication for systemic therapy was based on the presence of CRAB criteria according to the International Myeloma Working Group (IMWG) [8] . To compare elderly patients for whom HDT is considered a suitable option for primary treatment ( patients age 60-64 years) with elderly patients for whom the value of HDT remains uncertain ( patients ≥65 years) we chose 60 years as cutoff value for our analysis according to the definition proposed by the World Health Organization. Results for patients <60 years treated with HDT in our department are available as supplementary Figure S1 , available at Annals of Oncology online. Patients were stratified by age into three different groups (60-64, 65-69 and 70-75 years). For risk stratification before HDT, we used the International Staging System (ISS) calculated from β2-microglobulin and albumin serum levels at primary diagnosis [9] . Additionally, in 165 patients (82%), results from interphase fluorescence in situ hybridization (FISH) on CD138-purified plasma cells [10] were available. We assessed for the following aberrations which have been reported to be associated with adverse outcome after HDT: t(4;14); del17p; gain1q21 (>3 copies) [10] . The thresholds for deletions, gains and translocations were set at 10%. Patient characteristics are summarized in Table 1 .
induction therapy and stem cell mobilization
Patients received a median of three (2-6) cycles of induction therapy before stem cell mobilization and harvest. ) divided and administered separately on days -3 and -2 before ASCT. In seven patients (4%), a single application of 100 mg/m 2 melphalan was used due to renal function impairment (creatinine clearance <40 ml/min). Tandem ASCT was carried out in 43 patients (21%). Four to six weeks after ASCT patients were followed up in our outpatient clinic for reevaluation and initiation of maintenance therapy. A summary of the used HDT and maintenance therapy can be found in Table 1 .
response assessment and follow-up
Assessment of treatment response according to the IMWG guidelines [11] was carried out after induction chemotherapy ∼30 days before and 4-6 weeks after ASCT at our institution. IMWG response criteria were modified to include near CR (nCR) [12] . Treatment-related mortality (TRM) was defined as death during the first 100 days after ASCT.
statistical analysis
Statistical analysis was carried out with SPSS 21 (IBM, Chicago, IL). The Kruskall-Wallis test was used to analyze differences for continuous variables (transfused blood products, days to engraftment, days in hospital, days with fever and intravenous antibiotics/antimycotics) between the three different age groups. Nominal variables (applied therapy, remission rates before and after HDT) were analyzed with the χ 2 test. Event-free survival (EFS) was defined as the time from ASCT to relapse/progression or death from the disease. Overall survival (OS) was defined as the time from ASCT to death from any cause. Kaplan-Meier curves were used to determine EFS as well as OS and the log-rank test was applied to identify differences between the different groups. To evaluate the impact of age, ISS, cytogenetic aberrations, remission before and after HDT, application of tandem ASCT and maintenance therapy on EFS and OS, uni-and multivariate Cox proportional hazard (PH) regression analyses was carried out. P-values of <0.05 were considered significant. results engraftment, need of supportive care and early mortality after HDT When comparing patients regarding days to leucocyte and platelet recovery as well as number of transfused thrombocyte and erythrocyte concentrates after HDT, we found no significant differences between the three age groups. There was also no difference between these groups when looking at the inpatient days after HDT with ASCT, the days with fever >38.5°C as well as the days with intravenous antibiotic or antimycotic treatment. Overall, five patients (60-64 years: n = 3; 65-69 years: n = 1; 70-75 years: n = 1) had to be admitted to the intensive care unit: four patients with respiratory decompensation due to HSVpneumonia (n = 2) and pulmonary aspergillosis (n = 2) and one patient because of septic shock. Three patients died during the first 100 days after HDT with ASCT (60-64 years: n = 2; 65-69 years: n = 1; 70-75 years: n = 0), resulting in a TRM of 1.5%. Two patients died to septic shock while, in one patient, the cause of death could not be identified.
remission before and after HDT
After induction therapy, CR or nCR was achieved in 18% of all patients. HDT increased the nCR + CR rate to 35%. When comparing nCR + CR rates before/after HDT between the three different age groups, no significant differences were found (60-64 years: 19%/38%; 65-69 years: 16%/33%; 70-75 years: 19%/31%).
Patients treated with novel agents during induction therapy showed significantly higher nCR + CR rates before and after HDT (27%/43%) compared with patients treated without novel agents (1%/20%, P < 0.001, respectively).
clinical outcome of HDT and prognostic factors
The data on progression and survival status were collected in February 2013 with a median follow-up estimated by reverse Kaplan-Meier method of 37 months. The median EFS in the analyzed cohort was 24 months, the median OS was not reached with an OS of 83% at 72 months after HDT. Pairwise comparison of Kaplan-Meier curves for EFS and OS did not show significant differences between the three different age groups (median EFS: 60-64 years: 27 months; 65-69 years: 23 months; 70-75 years: 23 months; median OS: not reached; Figure 1A ). Cox PH analysis of EFS and OS (results summarized in Table 2 ) showed that age was not a risk factor for adverse outcome in our cohort of 202 patients between 60 and 75 years. Uni-and multivariate analyses revealed that ISS at diagnosis, cytogenetic aberrations from FISH and remission after HDT were the most relevant prognostic factors for EFS and OS ( Table 2 ). The application of novel agents or interferon-α as maintenance therapy after ASCT had a significant impact on Table 2 ). Only in univariate analysis, the performance of tandem ASCT had significant impact on EFS (Table 2) . No effect of tandem ASCT or maintenance therapy on OS was found in univariate or multivariate analysis.
combining ISS and cytogenetic data from FISH for further analysis
As described above, we found a significant impact of the ISS score on EFS and OS in our elderly patients after HDT. However, risk assessment did not allow to differentiate between patients with ISS stage II (median EFS: 22 months) and stage III (median EFS: 20 months). We therefore combined ISS data with results from cytogenetic testing, as described previously [10, 13] . Data for both ISS and cytogenetic testing were available in 161 patients. In that way, three different risk groups were stratified: the low-risk group (n = 69) included patients with no high-risk cytogenetic aberrations and ISS I. Intermediate-risk (n = 81) was defined by the presence of high-risk cytogenetic aberrations and ISS I or the absence of high-risk cytogenetic aberrations in combination with ISS II or III. Patients in the high-risk group (n = 11) had high-risk cytogenetic aberrations and ISS II or III. By combining information on ISS and cytogenetic testing we were able to discriminate between the three different risk groups regarding EFS and OS ( Figure 1B) . Patients in the low-risk group had a significant longer median EFS (45 months) and OS (not reached) than patients in the intermediate (EFS: 23 months; OS: not reached) and high-risk group (EFS: 13 months; OS: 32 months; P < 0.01, respectively). Furthermore, significant differences for EFS for patients in the intermediate-risk group compared with the highrisk group were found ( Figure 1B ; P < 0.05).
discussion
In the past decade the combination of HDT followed by ASCT with novel agents substantially improved the outcome of younger patients with MM [2] . However, the safety and efficacy of HDT in patients older than 65 years remains uncertain. Although Badros et al. [14] demonstrated that the TRM of 16% with MEL200 in patients >70 years can be reduced to 2% by dose reduction, recent retrospective studies showed that HDT with MEL200 is also feasible for selected elderly patients with MM [15] [16] [17] [18] . In our retrospective analysis, we also found no significant differences among three different age groups (60-64, 65-69 and 70-75 years) regarding engraftment after ASCT, need for supportive care and TRM. Remarkably, no patient between 70 and 75 years died because of early complications due to HDT. Furthermore, uni-and multivariate analyses demonstrated that age had no influence on EFS and OS after HDT and response rates and rates of CR were not different in the different age groups. The major downside of the currently available studies on HDT in elderly myeloma patients-either with MEL100 or MEL200-is the fact that most studies were carried out before the introduction of novel agents and the incorporation of maintenance therapy in the HDT concept. This might explain the relatively low nCR + CR rates reported in the prospective trials of MEL100 from Italy (25% [6] ) and France (18% [5] ) and the inferiority of MEL100 treatment without new drugs compared with MPT shown in the IFM study. Correspondingly, Palumbo et al. demonstrated in a prospective trial of 102 patients between 65 and 75 years that CR rates after HDT substantially improved when MEL100 was combined with a bortezomib-based induction therapy up to 38% [7] . This is in agreement with our results of nCR + CR rates after HDT of 43% in the group receiving novel agents during induction therapy compared with 20% in patients treated without novel agents. The interpretation of this finding is limited by the fact that novel agents during induction therapy were not equally distributed in our cohort and only 37% of all patients were treated without novel agents.
In the study by Palumbo et al., CR rates increased to 66% by adding a lenalidomide consolidation and maintenance therapy [7] . The role of maintenance therapy after ASCT in younger myeloma patients has been discussed extensively in the last years [19] . With our present study, we demonstrate that maintenance therapy with a novel agent or interferon also improves EFS of elderly patients eligible for HDT. However, due to the small number of patients treated with interferon (12%), we are not able to draw general conclusions and, given the common side-effects, especially in elderly patients and the positive effect only in this small group of patients, we do not recommend the routine use of interferon.
In younger patients eligible for HDT, risk stratification based on the ISS and cytogenetic aberrations as detected by FISH is widely accepted [20] . A recent study by the IFM demonstrated the prognostic significance of t(4;14) and del17p in elderly patients treated with MP-based regimens. Interestingly, they showed a decreased prevalence of high-risk aberrations, 14) , with increasing age [21] . This is partially in line with our data since no patient >70 years had t(4;14). However, high-risk cytogenetics were more prevalent in patients >70 years in our study. This might be explained by the fact that we also classified gain1q21 as high-risk aberration based on previously published results [10] . Our data reveal that risk assessment according to ISS and cytogenetic evaluation is also highly relevant for elderly patients eligible for HDT. We furthermore demonstrate that combining ISS and cytogenetic risk stratification identifies three subgroups of elderly patients with a different prognosis after HDT. This is in line with previous results from a large prospective trial including younger patients with newly diagnosed MM [10] . The combined information about cytogenetics and ISS was superior, especially to predict EFS compared with ISS staging only. The reason for this finding might be that the ISS was initially evaluated to predict OS and not EFS [9] . We therefore conclude that risk assessment according to ISS and cytogenetic analysis should be carried out routinely in elderly patients eligible for ASCT. Especially since previous studies indicated that the effect of maintenance after HDT is influenced by the detected cytogenetic aberrations [10] . Evaluating our data, it has to be taken into account that especially the oldest group of patients analyzed in the current study is highly selected by the treating physicians. This selection was rather based on previous experiences of our center than a structured assessment of comorbidities. A recent retrospective analysis of over 1400 patients from four randomized trials proposed to take into account not only the age but also comorbidities of the elderly patients [22] . Because of the retrospective character of our study, we were not able to systematically assess comorbidities. However, we support the proposed structured analysis especially in this more vulnerable cohort of patients in future trials. Another limitation of the current study is the small number of patients between 70 and 75 years. Especially in this population, prospective clinical trials are needed to compare sequential treatment of novel agents and HDT with established regimens like MPT and VMP.
In summary, we demonstrate with the current analysis that HDT with MEL200 is safe in selected elderly patients with newly diagnosed MM. The application of novel agents as induction/maintenance therapy improves response as well as outcome and should be implemented into the HDT concept in elderly patients. ISS and cytogenetic aberrations should be used for risk stratification of elderly. references
